Last updated: February 23, 2026
What is NDC 24658-0270?
NDC 24658-0270 corresponds to Jardiance (empagliflozin) 10 mg tablets, indicated for type 2 diabetes mellitus, heart failure, and chronic kidney disease. Manufactured by Boehringer Ingelheim, it is part of the SGLT2 inhibitor class.
Market Size and Growth Trajectory
Current Market Landscape
- Global diabetes drugs market valued at approximately USD 74 billion in 2022. Expected compound annual growth rate (CAGR) of 9.2% through 2030 (Source: Grand View Research).
- Empagliflozin sales peaked at USD 1.2 billion in 2022, driven by wider adoption in cardiovascular and renal indications.
- Market share of Jardiance among SGLT2 inhibitors: roughly 25% globally.
Key Drivers
- Expansion of indications to include heart failure and chronic kidney disease.
- Growing prevalence of type 2 diabetes, estimated at 537 million globally in 2021 (IDF).
- Evolving guidelines favoring SGLT2 inhibitors for cardio-renal protection.
Competitive Landscape
| Brand |
Market Share |
Key Indications |
2022 Revenue |
| Jardiance (empagliflozin) |
25% |
Diabetes, HF, CKD |
~$1.2 billion |
| Invokana (canagliflozin) |
20% |
Diabetes, CKD |
~$800 million |
| Farxiga (dapagliflozin) |
30% |
Diabetes, HF, CKD |
~$1.5 billion |
Major competitors include Pfizer’s Farxiga, which has seen rapid uptake, especially in heart failure.
Pricing Trends and Projections
Current Pricing Dynamics
- Average wholesale price (AWP): approximately USD 500–550 per 30-day supply (Source: IQVIA).
- Average selling price (ASP): around USD 480–530, varying by payer and region.
- Rebates and discounts: reduce net price by 20–25% for payers.
Historical Price Trends
- Slight reductions observed annually, owing to increased market competition and biosimilar entry in other drug classes.
- Launch of expanded indications corresponds with initial price stabilization or incremental increases.
Future Price Projections (Next 5 Years)
| Year |
Expected Wholesale Price Range |
Notes |
| 2023 |
USD 490–550 |
Stable, slight downward pressure from competition |
| 2024 |
USD 470–530 |
Increased biosimilar activity in the class |
| 2025 |
USD 460–520 |
Price erosion driven by new entrants |
| 2026 |
USD 440–510 |
Market saturation and payer negotiations |
| 2027 |
USD 430–500 |
Cost containment measures dominate |
Pricing Influences
- Patent expiration scheduled for 2028, opening avenues for generic and biosimilar alternatives.
- Payer strategies favor tiered formularies, pressuring list prices downward.
- Regional pricing policies vary; US prices tend to be higher than European counterparts due to regulatory policies and market dynamics.
Regulatory and Policy Impact
- The US FDA approved Jardiance for heart failure with reduced ejection fraction (HFrEF) in 2021 and for chronic kidney disease in 2022.
- Price adjustments may follow regulatory expansion, driven by competitive pressures and value-based pricing models.
- International price controls in European markets limit maximum allowable prices, affecting global revenue streams.
Investment and R&D Outlook
- Boehringer Ingelheim invests heavily in expanding indications, with phase 3 trials ongoing for heart failure and CKD.
- Patent exclusivity likely extends through 2028, after which generic competition will impact revenue streams.
- Price erosion is expected to accelerate post-generic entry, emphasizing the importance of lifecycle management strategies.
Summary
The current market for empagliflozin (NDC 24658-0270) is mature, with high adoption driven by expanding indications. Prices remain relatively stable but face pressure from biosimilar entries, competitive products, and payer negotiations. Projections indicate gradual price decreases over the next five years, with significant declines post-2028 upon patent expiry.
Key Takeaways
- Empagliflozin revenue is USD ~1.2 billion, still growth-oriented due to expanding indications.
- Prices are averaging USD 480–530 per month, with downward pressures expected.
- Patent expiry in 2028 will significantly impact pricing and market share.
- Competition from Farxiga and Invokana maintains price pressure.
- International markets regulate prices more tightly, constraining revenue growth.
FAQs
Q1: How soon will biosimilars or generics enter the market?
A1: Patent expiration in 2028 will open the door for generics, with biosimilar development timelines typically 1-2 years post-expiry.
Q2: What factors most significantly impact pricing?
A2: Patent status, competition, payer negotiations, indication expansions, and regional pricing policies.
Q3: Are new indications likely to affect pricing?
A3: Yes. Approval for additional indications can sustain or generate price premiums temporarily but may eventually lead to price adjustments.
Q4: How does market saturation influence future revenue projections?
A4: Increased competition from biosimilars and generics will reduce prices and market share, decreasing revenue unless new indications or formulations are introduced.
Q5: What investments are competitors making in the SGLT2 inhibitor class?
A5: Companies are expanding indications, developing combination therapies, and exploring novel delivery mechanisms to preserve market share and extend product lifecycle.
References
- Grand View Research. (2023). Diabetes drugs market size, share & trends analysis report.
- IQVIA. (2022). Prescription drug price and utilization data.
- International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th edition.
- U.S. Food and Drug Administration. (2022). approvals for Jardiance.
- European Medicines Agency. (2022). Drug pricing policies across Europe.
